We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

71 hedge funds and large institutions have $22.2M invested in Eiger BioPharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

650% more call options, than puts

Call options by funds: $105K | Put options by funds: $14K

24% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 21

12% less funds holding

Funds holding: 81 → 71 (-10)

23% less capital invested

Capital invested by funds: $28.9M → $22.2M (-$6.67M)

50% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 16

Holders
71
Holders Change
-10
Holders Change %
-12.35%
% of All Funds
1.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
26
Reduced
21
Closed
16
Calls
$105K
Puts
$14K
Net Calls
+$91K
Net Calls Change
-$164K

Top Buyers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
+$4M
2
SAM
Simplify Asset Management
Nevada
+$1.7M
3
6CM
683 Capital Management
New York
+$1.29M
4
UOC
UBS O'Connor
Illinois
+$654K
5
Renaissance Technologies
Renaissance Technologies
New York
+$249K

Top Sellers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
-$2.47M
2
Morgan Stanley
Morgan Stanley
New York
-$1.17M
3
Millennium Management
Millennium Management
New York
-$1.17M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$747K
5
AQR Capital Management
AQR Capital Management
Connecticut
-$449K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
51
UBS Group
Switzerland
$12.2K -$3.49K -75 -14%
Principal Financial Group
52
Principal Financial Group
Iowa
$12.1K -$884 -19 -4%
Millennium Management
53
Millennium Management
New York
$12K -$1.17M -25,111 -98%
CS
54
Credit Suisse
Switzerland
$9.42K – – –
Fidelity Investments
55
Fidelity Investments
Massachusetts
$8.68K -$25K -537 -63%
AB
56
Amalgamated Bank
New York
$6K +$186 +4 +2%
Allspring Global Investments
57
Allspring Global Investments
North Carolina
$5.54K +$4.79K +103 +100%
Legal & General Group
58
Legal & General Group
United Kingdom
$4.54K – – –
Citigroup
59
Citigroup
New York
$3.08K -$12.8K -275 -71%
Royal Bank of Canada
60
Royal Bank of Canada
Ontario, Canada
$3K -$5.91K -127 -55%
AIP
61
Ameritas Investment Partners
Nebraska
$2.79K – – –
National Bank of Canada
62
National Bank of Canada
Quebec, Canada
$1.15K – – –
CUAMC
63
China Universal Asset Management Company
China
$535 +$233 +5 +33%
AAS
64
Ameritas Advisory Services
Nebraska
$391 +$605 +13 New
SIS
65
Sound Income Strategies
Florida
$359 – – –
FDCDDQ
66
Federation des caisses Desjardins du Quebec
Quebec, Canada
$332 – – –
TFA
67
Toth Financial Advisory
Virginia
$301 +$512 +11 New
PCTC
68
Perkins Coie Trust Company
Washington
$158 – – –
Assenagon Asset Management
69
Assenagon Asset Management
Luxembourg
– -$747K -21,092 Closed
PAWC
70
P.A.W. Capital
Connecticut
– -$295K -8,333 Closed
Prudential Financial
71
Prudential Financial
New Jersey
– -$236K -6,680 Closed
Squarepoint
72
Squarepoint
New York
– -$199K -5,633 Closed
Citadel Advisors
73
Citadel Advisors
Florida
– -$187K -4,023 Closed
CC
74
Carlson Capital
Texas
– -$82.6K -2,333 Closed
AGM
75
Alpine Global Management
New York
– -$73K -2,064 Closed
1 2
3
4

EIGR Hedge Fund Activity: Q1 2023 in Review

71 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2023, worth a combined $22.2M — down 23% from $28.9M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of EIGR and 8 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 26 added.

The largest buyer was Ameriprise, adding an estimated $4M. The largest seller was Barclays, cutting an estimated $2.47M.

  • 71 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2023, down from 81 in Q4 2022.
  • Funds reported $22.2M of Eiger BioPharmaceuticals, Inc. stock for Q1 2023, down 23% quarter-over-quarter.
  • 8 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2023 and 16 closed out, a net change of -8 holders.
  • The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2023 was Ameriprise, an estimated $4M added.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2023 was Barclays, an estimated $2.47M sold.

Based on aggregated 13F filings for Q1 2023.